SNN logo

SMITH & NEPHEW PLC -SPON ADR

SNNNYSE
πŸ† #688 by market capEarnings Feb 23US Equity
$29.84β–Ό $0.17 (βˆ’0.57%)
πŸŒ™ After hours$29.84β–² 0.00%Regular close Β· extended-hours price shown
1hβ€”
24hβ–Ό 0.6%
7dβ–² 0.4%
14dβ–Ό 7.8%
30dβ–² 0.1%
1yβ–Ό 18.9%
🏦Market Cap
$12.53B
Mid Cap
πŸ“ˆRevenue Growth (YoY)
+6.1%
Slowing
πŸ“ŠGross Margin
68.2%
High
πŸ’΅FCF Margin
13.3%
Healthy
βš–οΈP/S Ratio
1.9x
Cheap
Otter Score
60
Fair

Trading Snapshot

Day Range
$29.47 – $30.39
52-Week Range
$28.56 – $38.79
Volume
$2.35B
Avg Volume
$2.53B
Shares Outstanding
419.9M
Next Earnings
Oct 9, 2026

Fundamentals Snapshot

Annual Revenue
$6.16B
Last Q Revenue
$3.10B
P/E Ratio
19.4
P/S Ratio
1.9x
EPS (TTM)
$1.51
Dividend Yield
2.66%

Why Investors Own SNN

  • βœ“High-growth profile β€” revenue up +13.3% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 72% gross margin and 16% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)
$6.16Bβ–² +8.8% YoY
Gross Margin (TTM)
72.1%β–² +0.9% YoY
Operating Income (TTM)
$1.84Bβ–² +8.8% YoY
Free Cash Flow (TTM)
$955Mβ–² +8.8% YoY

About SMITH & NEPHEW PLC -SPON ADR

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. The company also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, it provides arthroscopic enabling technologies comprising fluid management equipment for surgical access, cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, the company offers advanced wound care products for the treatment and prevention of acute and chronic wounds, leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.

🦦

Otter Score Breakdown

β“˜
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
Overall Score
Fair
60/100

Analyst Ratings

β“˜
Consensus
Buy
24 analysts
Strong Buy5
Buy7
Hold12
Sell0
Strong Sell0
Ratings as of Aug 2026

Latest News & Updates